Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-04-09

Clinical Trial Update: Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) [Phase 3]

View source ↗

Summary

Phase 3 PROSERA trial evaluating Seralutinib for pulmonary arterial hypertension has completed. The update covers efficacy and safety in adult participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Seralutinib (Seralutinib)

Snippet

Sponsor: GB002, Inc. | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: COMPLETED